Bioatla to announce first quarter 2022 financial results and provide business highlights on may 4, 2022

San diego, april 08, 2022 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody and other protein therapeutics, today announced that it plans to host a conference call and webcast on wednesday, may 4, 2022 at 4:30 p.m. eastern time to discuss its financial results for the quarter ended march 31, 2022, and provide an interim topline data update from the mecbotamab vedotin (ba3011) phase 2 study in sarcoma as well as an operational update on our ongoing clinical programs, including ba3011, ozuriftamab vedotin (ba3021) and cab-ctla-4 (ba3071).
BCAB Ratings Summary
BCAB Quant Ranking